Cargando…

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting

BACKGROUND: Desmopressin is an important treatment option in nonsevere hemophilia A because it has several benefits compared with factor (F) concentrates, including no inhibitor risk and much lower costs. Despite these advantages, data are limited on the real‐world use of desmopressin in the treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zwagemaker, Anne‐Fleur, Kloosterman, Fabienne R., Coppens, Michiel, Gouw, Samantha C., Boyce, Sara, Bagot, Catherine N., Beckers, Erik A. M., Brons, Paul, Castaman, Giancarlo, Eikenboom, Jeroen, Jackson, Shannon, Kruip, Marieke J. H. A., Leebeek, Frank W. G., Meijer, Karina, Nieuwenhuizen, Laurens, Pabinger, Ingrid, Fijnvandraat, Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433315/ https://www.ncbi.nlm.nih.gov/pubmed/36090159 http://dx.doi.org/10.1002/rth2.12777

Ejemplares similares

Hemophilia management: Huge impact of a tiny difference
por: Kloosterman, Fabienne, et al.
Publicado: (2020)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy
por: Romano, Lorenzo G.R., et al.
Publicado: (2023)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020)

Desmopressin in moderate hemophilia A patients: a treatment worth considering
por: Loomans, Janneke I., et al.
Publicado: (2018)

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
por: Schütte, Lisette M, et al.
Publicado: (2019)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Desmopressin testing in von Willebrand disease: Lowering the burden
por: Heijdra, Jessica M., et al.
Publicado: (2022)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study
por: van Balen, Erna C., et al.
Publicado: (2022)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study
por: Isfordink, Cas J., et al.
Publicado: (2021)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2022)

Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study
por: Schep, Sarah J., et al.
Publicado: (2020)

In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype
por: Verhagen, Marieke J.A., et al.
Publicado: (2023)

Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority?
por: Schütte, Lisette M., et al.
Publicado: (2020)

Sports participation and physical activity in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
por: Preijers, T., et al.
Publicado: (2021)

Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2021)

Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9
por: Stoof, Sara C. M., et al.
Publicado: (2018)

Hemophilia A and B: molecular and clinical similarities and differences
por: Castaman, Giancarlo, et al.
Publicado: (2019)

Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A— A Systematic Review and Meta-Analysis
por: Abdi, A., et al.
Publicado: (2020)

Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis
por: Croles, F Nanne, et al.
Publicado: (2017)

Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects
por: Blaauwgeers, Maaike W., et al.
Publicado: (2020)

Congenital platelet disorders and health status–related quality of life
por: Blaauwgeers, Maaike W., et al.
Publicado: (2019)

The Arrival of Gene Therapy for Patients with Hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2022)

Professional functioning of young adults with congenital coagulation disorders in the Netherlands
por: Limperg, Perrine F., et al.
Publicado: (2019)

Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis
por: Oomen, Ilja, et al.
Publicado: (2022)

Patients’ and health care providers’ perspectives on quality of hemophilia care in the Netherlands: a questionnaire and interview study
por: Brands, Martijn R., et al.
Publicado: (2023)

Comparative response of Desmopressin versus Combination Therapy (Desmopressin + Oxybutynin) in Children with Nocturnal Enuresis
por: Kazi, Asiya, et al.
Publicado: (2020)

Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A
por: ten Ham, Renske M.T., et al.
Publicado: (2022)

Antifibrinolytic Agents: Aprotinin, and Desmopressin
por: Bajaj, Pramila
Publicado: (2009)

Desmopressin Acetate in Intracranial Haemorrhage
por: Kapapa, Thomas, et al.
Publicado: (2014)

New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome
por: Leebeek, Frank W. G.
Publicado: (2021)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ah77bpcs8bl39vkp0pa3ljthb6